Loading...

RVMD REVOLUTION MEDICINES INC Capital Structure Changes 8-K Filing

RVLT

RVMD

REVOLUTION MEDICINES INC

(RVMD)

2026 8-K

Financial Results Announcement

New Debt Issuance

Equity Offering Details

Drug Trial Results

Financial Results Announcement

Financial Results Report

FDA Voucher Granted

Pipeline Update

Financial Statements

Strategic Alliances

Financial Statements

Financial Results

Pipeline Updates

Financial Results

Clinical Trial Update

Pipeline Update

Financial Results and Board...

Pipeline Updates and Financ...

Annual Meeting of Stockholders

Financial Results Announcement

Financial Results Announcement

Amendment to 8-K

Acquisition of EQRx, Inc.

Financial Results Announcement

Merger of Equals

Pipeline Updates

Pipeline Updates

Financial Results Announcement

Merger Agreement

Annual Meeting of Stockholders

Financial Results Announcement

Underwriting Agreement

Financial Results Announcement

Results of Operations and F...

External Links:

Revolution Medicines, Inc. reported issuing $500 million in 0.50% Convertible Senior Notes due in 2033 on April 17, 2026. This filing indicates a significant financial obligation for the company, allowing conversions at approximately $198.80 per share.

AI Assistant

REVOLUTION MEDICINES INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.